Utmost Group reports 5.71% stake in TriSalus

TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026.

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026. The filing notes ownership declined by more than 1% versus 09/30/2025 due to an increase in outstanding shares. The report is signed by Ian Maidens, Group CFO, on 05/05/2026.

Insights

Institutional Ownership Analyst

Utmost Group PLC holds a 5.71% stake in TriSalus as of 03/31/2026.

Utmost Group PLC reports sole voting and dispositive power over 3,503,385 shares, representing 5.71% of the class. The filing explicitly ties a >1% ownership decline to an increase in outstanding shares between 09/30/2025 and 03/31/2026.

Cash‑flow treatment or planned dispositions are not disclosed in the excerpt; subsequent filings would state any sale programs or schedules.

Regulatory Compliance Specialist

The Schedule 13G is a passive reporting format by a regulated non‑U.S. institution.

The filer indicates reliance on a foreign regulatory scheme and certifies comparability to specified U.S. equivalents. The filing includes identification of a subsidiary, Utmost Luxembourg S.A., and is signed by the Group CFO on 05/05/2026.

This is a disclosure of beneficial ownership; it does not, by itself, signal trading intent.

Key Figures

Beneficial ownership: 3,503,385 shares Percent of class: 5.71% Comparison date: 09/30/2025 +1 more

4 metrics

Beneficial ownership 3,503,385 shares as of 03/31/2026

Percent of class 5.71% as of 03/31/2026

Comparison date 09/30/2025 prior reference date for >1% ownership decline

Filing signatory Ian Maidens - Group CFO signature dated 05/05/2026

Key Terms

Schedule 13G, beneficially owned, sole dispositive power, foreign regulatory scheme

4 terms

Schedule 13G regulatory

"On 31 March 2026, Utmost Group PLC held 3,503,385 units of TriSalus Life Sciences's common shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned regulatory

"Amount beneficially owned: 3,503,385 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 3,503,385"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

foreign regulatory scheme regulatory

"the foreign regulatory scheme applicable to (J) A non-U.S. institution"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Utmost Group PLC report in TriSalus (TLSI)?

Utmost Group PLC reports beneficial ownership of 3,503,385 shares, representing 5.71% of TriSalus common stock as of 03/31/2026. The filing states sole voting and dispositive power over these shares.

Did Utmost Group PLC increase or decrease its ownership in TLSI?

The filing states Utmost's ownership decreased by more than 1% compared to 09/30/2025, citing an increase in the company's outstanding shares as the cause rather than additional disposals by Utmost.

Who signed the Schedule 13G for TLSI and when?

The Schedule 13G was signed by Ian Maidens, Group CFO of Utmost Group PLC, on 05/05/2026, certifying the foreign regulatory comparability statement included in the filing.

Does the Schedule 13G indicate Utmost plans to sell TLSI shares?

The filing discloses beneficial ownership and voting/dispositive power for 3,503,385 shares but does not state any planned sales or distribution methods; no disposition program is described in the provided excerpt.

Which entities are identified in the filing as related to the holding?

The filing names Utmost Group PLC as filer and lists Utmost Luxembourg S.A. (address and registration number B37604) as the subsidiary identified under the parent holding company disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 08:30 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TriSalus Life Sciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

89680M101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 89680M101

1

Names of Reporting Persons

Utmost Group PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,503,385.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,503,385.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,503,385.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.71 %

12

Type of Reporting Person (See Instructions)

IC, HC, FI

Comment for Type of Reporting Person: On 31 March 2026, Utmost Group PLC held 3,503,385 units of TriSalus Life Sciences's common shares, representing 5.71% of the outstanding shares. Compared to 30 September 2025, the ownership of Utmost Group PLC in the company decreased by more than 1% as a result of an increase in outstanding shares of the company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TriSalus Life Sciences, Inc.
(b)	Address of issuer's principal executive offices: 6272 W. 91st Ave. Westminster, CO 80031
Item 2.
(a)	Name of person filing: Utmost Group PLC
(b)	Address or principal business office or, if none, residence: Saddlers' House 5th Floor, 44 Gutter Lane, London, United Kingdom, EC2V 6BR
(c)	Citizenship: United Kingdom
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 89680M101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Insurance Company
Item 4.	Ownership
(a)	Amount beneficially owned: 3,503,385 shares
(b)	Percent of class: 5.71%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,503,385
	(ii) Shared power to vote or to direct the vote: None
	(iii) Sole power to dispose or to direct the disposition of: 3,503,385
	(iv) Shared power to dispose or to direct the disposition of: None
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Utmost Luxembourg S.A. - 4, rue Lou Hemmer, L1748 Luxembourg, Luxembourg (Registration number: B37604)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to (J) A non-U.S. institution that is the functional equivalent of any of the institutions listed in ??240.13d 1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institutio is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Utmost Group PLC

Signature:	/s/ Ian Maidens
Name/Title:	Ian Maidens - Group CFO
Date:	05/05/2026